Prospects for anxiolytic therapy: a reflection from different viewpoints

Drug Discovery Today

Volumn 3, Issue 10, 1998, Pages 471-479

  Millet, Bruno ^a   Bayle, Franck Jean ^a   Olié, Jean Pierre ^a  

^a Serv Hosp Univ Psychiat Hop S ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; BENZODIAZEPINE DERIVATIVE; BETA CARBOLINE DERIVATIVE; BROMAZEPAM; BUSPIRONE; CARPIPRAMINE; CHLORDIAZEPOXIDE; CLORAZEPATE; DIAZEPAM; GEPIRONE; IPSAPIRONE; LORAZEPAM; NEFAZODONE; ONDANSETRON; OXAZEPAM; PRAZEPAM; RITANSERIN; SEROTONIN 1A AGONIST; SEROTONIN 2 ANTAGONIST; SEROTONIN 3 ANTAGONIST; TROPISETRON; ZACOPRIDE;

ANXIETY; ANXIETY NEUROSIS; HUMAN; MENTAL DEFICIENCY; OBSESSION; PANIC; PHOBIA; POSTTRAUMATIC STRESS DISORDER; REVIEW;

EID: 0031786593     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(98)01239-2     Document Type: Review

References (61)

1. Marks I. J. Psychopharmacol. 1:1987;6-12.
2. Fyer, A.S., Mannuzza, S. and Coplan, J.D. (1995) in Comprehensive Text Book of Psychiatry (6th edn) (Kaplan, H.I. and Sadock, V.V., eds), pp. 573-582, Williams & Wilkins.
3. Klein, D.F. (1964) in Anxiety: New Research and Changing Concepts (Klein, D.F. and Rabkin, J.G., eds), pp. 235-263, Raven Press.
4. American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders (3rd edn, revised).
5. Barr Taylor, C. (1993) in The American Psychiatric Textbook of Psychopharmacology (Vol. 31), pp. 641-655.
6. Shader, R.I. and Greenblatt, D.J. (1995) in Psychopharmacology: The Fourth Generation of Progress (Vol. 113) (Bloom, F.E. and Kupfer, D.J., eds), pp. 1341-1348, Raven Press.
7. Woods J.H., Katz J.L., Winger G. Pharmacol. Rev. 44:1992;151-347.
8. Shader R.I., Greenblatt D.J. New Engl. J. Med. 328:1993;1398-1405.
9. Cross-National Collaborative Panic Study, Second Phase Investigators (1992) Br. J. Psychiatry 160, 191-192.
10. Marks I.et al. Br. J. Psychiatry. 160:1992;202-205.
11. World Health Organization (1996) Rational Use of Benzodiazepines.
12. Balter M.B., Ban T.A., Uhlenhuth E.H. Hum. Psychopharmacol. 8:1993;253-261.
13. Markku L.et al. J. Clin. Psychopharmacol. 3:1983;88-96.
14. Seppala T., Linnoila M., Mattila M.J. Drugs. 17:1979;389-408.
15. Girre C.et al. Presse Med. 17:1988;1135-1138.
16. Sellal F.et al. Psychopharmacology. 108:1992;371-379.
17. Rosenbaum J.F.et al. Am. J. Psychiatry. 141:1984;792-793.
18. Rickels K.et al. J. Am. Med. Assoc. 250:1983;767-771.
19. Tyrer P. Lancet. ii:1983;1402-1406.
20. Noyes R.et al. J. Clin. Psychiatry. 49:1988;382-389.
21. Balter M., Manheimer D., Mellinger G. Curr. Med. Res. Opin. 8(Suppl. 84):1983;5-20.
22. Olié, J-P. and Millet, B. (1997) Future Therapies for an Anxious World, 24-26 November, Paris, France.
23. Morselli P.L. Pharmacopsychiatry. 23(Suppl. 2):1990;129-135.
24. Ballenger J.C.et al. Psychopharmacol. Bull. 27(2):1991;171-179.
25. Bougerol, T., Lancon, C. and Llorca, P.M. (1997) Encycl. Med. Chir. 37-860-B-50, 178, Elsevier.
26. Ferreri M., Albi J.M. Encephale. 13(6):1987;357-365.
27. Bersani G.et al. Acta Psychiatr. Scand. 83:1991;244-248.
28. Bressa G.M., Marini S., Gregori S. Int. J. Clin. Pharmacol. Res. 7:1987;111-119.
29. Katz R.J.et al. Biol. Psychiatry. 34:1993;41-44.
30. Fawcett J.et al. J. Clin. Psychiatry. 56(6):1995;37-42.
31. Lader, M.H. (1991) World Congress of Biological Psychiatry, 9 June, Florence, Italy.
32. Lecrubier V.et al. Psychopharmacology. 112:1993;129-133.
33. Greenshaw A.J., Silverstone P.H. Drugs. 53:1997;20-39.
34. Bradwejn J.et al. Arch. Gen. Psychiatry. 51:1994;486-493.
35. Van Vliet I.M., Westenberg H.G.M., Slaap B.R. Biol. Psychiatry. 42:1997;76-78.
36. Heilig M.et al. Neuropsychopharmacology. 8:1993;357.
37. Britton K.T.et al. Psychopharmacology. 86:1985;170.
38. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders (4th edn).
39. Fossey, M.D. and Lydiard, R.B. (1990) in Handbook of Anxiety (Vol. 4) (Noyes, R., Roth, M. and Burrows, G.D., eds), pp. 27-56, Elsevier.
40. Boulanger, T. (1995) Encephale XXI, 459-466.
41. Robins, L.N. and Regier, D.A. (1991) Psychiatric Disorders in America: the Epidemiologic Catchment Area Study, The Free Press, New York; Collier Macmillan Publishers, London.
42. Papp, L.A. and Gorman, J.M. (1995) in Comprehensive Text Book in Psychiatry (6th edn) (Kaplan, H.I. and Sadock, V.V., eds), pp. 611-615, Williams & Wilkins.
43. Tyrer P.et al. Acta Psychiatr. Scand. 85:1992;201-206.
44. Brown T.A., Barlow D.H., Liebowitz M.R. Am. J. Psychiatry. 151:1994;1272-1280.
45. Schweizer E. Psychiatr. Clin. North Am. 18(4):1995;843-857.
46. Brawman-Mintzer O.et al. Am. J. Psychiatry. 150:1993;1216-1218.
47. Noyes R.et al. J. Nerv. Ment. Dis. 180:1992;369-379.
48. Brown T.A., Barlow D.H. J. Consult. Clin. Psychol. 60:1992;835-844.
49. Massion A.O., Warshaw M.G., Keller M.B. Am. J. Psychiatry. 150:1993;600-607.
50. Rickels K., Schweizer E. Psychopharmacol. Bull. 31:1995;1.
51. Wittchen H.U.et al. Arch. Gen. Psychiatry. 51:1994;355-364.
52. Schweizer. E., Rickels, K. and Uhlenhuth, E.H. (1995) in Psychopharmacology: The Fourth Generation of Progress (Vol. 114) (Bloom, F.E. and Kupfer, D.J., eds), pp. 1349-1359, Raven Press.
53. Nagy L.M.et al. Arch. Gen. Psychiatry. 46:1989;993-999.
54. Rickels K.et al. Arch. Gen. Psychiatry. 45:1988;444-450.
55. Schweizer E.et al. Arch. Gen. Psychiatry. 50:1993;51-60.
56. Price, L.H. et al. (1995) in Psychopharmacology: The Fourth Generation of Progress (Vol. 111) (Bloom, F.E. and Kupfer, D.J., eds), pp. 1311-1323, Raven Press.
57. Cowley D.S., Arana G.W. Arch. Gen. Psychiatry. 47:1990;411-418.
58. Uhde T.W.et al. Biol. Psychiatry. 21:1986;1077-1081.
59. Hollander E.et al. Psychiatry Res. 37:1991;161-177.
60. Millet, B. et al. Biol. Psychiatry (in press).
61. Johnson M.R., Lydiard R.B. Psychiatr. Clin. North Am. 18(4):1995;681-725.